Physician profile
Catherine D Morris
NPI 1619984820
$1,891.14
in general payments reported to CMS, 2019-2025
24 companies · $97.30 in 2025
The $97.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $172 · 2022: $344 · 2023: $551 · 2024: $368 · 2025: $97.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.83 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $373.73 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $372.10 | 2019-2024 | Evenity, Prolia, Otezla |
| Novartis Pharmaceuticals Corporation | $143.17 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.00 | 2023 | |
| Glaxosmithkline, LLC. | $109.13 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Idorsia Pharmaceuticals US INC | $107.73 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $103.13 | 2020 | |
| Abbvie INC. | $97.76 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $84.00 | 2019-2023 | Farxiga |
| Nevro Corp. | $68.20 | 2022 | |
| Astellas Pharma US INC | $47.12 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $45.66 | 2019 | |
| Pfizer INC. | $40.39 | 2020-2022 | |
| Eisai INC. | $30.85 | 2025 | |
| Allergan, INC. | $23.57 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $19.90 | 2019 | |
| Harmony Biosciences LLC | $19.52 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.24 | 2022 | |
| Phadia US INC. | $15.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.51 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $14.90 | 2020 | |
| Exact Sciences Corporation | $13.58 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $12.23 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.